Evidence-based Evaluation and Mechanism of Shenhuang Granules in the Treatment of Sepsis
NCT06514339 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 410
Last updated 2025-08-22
Summary
Sepsis is a life-threatening organ dysfunction caused by the body's dysfunctional response to infection, most patients require treatment in the ICU, and is the leading cause of death worldwide. Over the years, the development of new drugs for the treatment of sepsis has failed without significant benefit in reducing mortality, and there is currently no effective drug treatment. Therefore, sepsis is a serious disease threatening the life and health of patients, causing a huge burden to society, and is a major problem in the medical field.
The pathogenesis of sepsis is complicated, and immune imbalance is the key mechanism. Suppression of host immune function may be the root cause of the increase in the long-term mortality of sepsis. Bidirectional immune regulation may be an important treatment plan to improve the survival rate and quality of life of sepsis patients. In recent years, the contribution of traditional Chinese medicine to sepsis has been highly valued at home and abroad. The treatment of sepsis by traditional Chinese medicine mainly plays the role of bidirectional immune regulation by dispelling the evil and supporting the right. Our team has achieved some results in the diagnosis and treatment of sepsis by using traditional Chinese medicine. Supported by National Natural Science Foundation of China (81774070). The team also found that magnolol can inhibit intestinal mucosal inflammation in sepsis, which was also supported by the National Natural Science Foundation of China (82174178). The team of Qhuang scholars inherit the academic experience of Zhu Liangchun, the master of Chinese medicine, warm and hot disease need not be limited to the law of wei, qi, ying, blood transmission, that is, the disease can be solved both outside and inside, breaking the three bans of warm and cold disease. On the basis of inheriting Zhu Liangchun's academic theory, the author put forward the early treatment rule of "truncation and reversal", and used to cleanse the "poison" and "save Yin" in the early stage of sepsis to quickly truncate the malignant development trend of sepsis. In the COVID-19 epidemic, we have found that patients with COVID-19 sepsis have "acute deficiency syndrome" in the early stage of clinical syndrome, which is an important factor leading to death. The clinical efficacy and mechanism of "Shenhuang Granules" in sepsis caused by non-novel coronavirus infection such as bacteria need to be further studied.
Conditions
Interventions
- DRUG
-
shenhuang granule
Traditional Chinese medicine compound "Shenhuang Granules" is developed by Professor Fang Bangjiang, a scholar in the team of Qi-Huang, which is composed of ginseng, rhubarb, dandelion, etc., with the effect of Fuzheng Guben, clearing heat and detoxification, promoting qi and promoting blood and detumification.
- DRUG
-
Placebo was provided by Tianjin Hongri Pharmaceutical Co., LTD., and was given orally or nasally (through gastric tube or intestinal tube) after dissolution of 100ml warm water (temperature about 40°) in 1 package twice a day.
Sponsors & Collaborators
-
Zhejiang University
collaborator OTHER -
Red Cross Hospital, Hangzhou, China
collaborator OTHER -
Ningbo Hospital of Traditional Chinese Medicine
collaborator UNKNOWN -
The First Affiliated Hospital of Zhejiang Chinese Medical University
lead OTHER
Principal Investigators
-
Wu JianNong, doctor · The First Affiliated Hospital of Zhejiang Chinese Medical University
-
Liu Shan, doctor · The First Affiliated Hospital of Zhejiang Chinese Medical University
-
Feng DanDan, master · The First Affiliated Hospital of Zhejiang Chinese Medical University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-07-01
- Primary Completion
- 2026-03-01
- Completion
- 2026-07-01
Countries
- China
Study Locations
More Related Trials
-
Improvement of Organ Function by Apigenin in Elderly Patients With Sepsis
NCT05999682 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Efficacy and Safety of Ta1 for Sepsis
NCT02867267 ·Status: COMPLETED ·Phase: PHASE3
-
Shenfu Injection Modulates Carotid Elasticity in Septic Shock
NCT06915506 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Oral Administration or Nasal Feeding of Huzhangxiefei Decoction for Treatment in Sepsis Induced Acute Lung Injury
NCT04940676 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of Electroacupuncture for ICU Sepsis Patients
NCT06666946 ·Status: RECRUITING ·Phase: NA
-
Novel Biomarkers Related Xuebijing Injection Improves Sepsis
NCT06920420 ·Status: NOT_YET_RECRUITING
-
Immunoregulatory Therapy for 2019-nCoV
NCT04268537 ·Status: UNKNOWN ·Phase: PHASE2
-
An Acupuncture Study for People At High Risk for Sepsis
NCT06344819 ·Status: RECRUITING ·Phase: PHASE2
-
Effect of Dexmedetomidine vs Esmolol or Placebo on Cerebral Hemodynamics in Septic Shock
NCT06169475 ·Status: COMPLETED ·Phase: NA
-
Pharmacokinetics of XueBiJing in Patients With Sepsis
NCT03475732 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Thymosin alpha1 for Severe Sepsis
NCT00711620 ·Status: COMPLETED ·Phase: NA
-
Neutrophil Elastase Inhibitor in Treatment of ARDS Patients With Mechanical Ventilation Caused by Sepsis
NCT05672472 ·Status: UNKNOWN ·Phase: NA
-
Safety and Efficacy of Extracorporeal Cytokine Hemoadsorption in Septic Shock in Critically Ill Cirrhotics
NCT03866083 ·Status: UNKNOWN ·Phase: NA
-
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Dose Exploration Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Characteristics of STC314 Injection Administered Intravenously in Sepsis Patients
NCT06548854 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
The Effect of Moderate-Dose Steroid Therapy in Sepsis
NCT01275638 ·Status: COMPLETED ·Phase: PHASE4
-
Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis
NCT02576457 ·Status: TERMINATED ·Phase: PHASE1
-
Anisodamine Critically Ill SeptIc Shock
NCT02442440 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Kukoamine B Mesilate in Sepsis Patients
NCT04803955 ·Status: RECRUITING ·Phase: PHASE2
-
The Effect and Mechanism of lncRNA NBR2 Regulating Endothelial Pyroptosis by Targeting GSDMD in Sepsis
NCT04427371 ·Status: UNKNOWN
-
Effects of Dexmedetomidine on Respiratory Function and Inflammatory Responses in Patient With Sepsis Undergoing Cleaning Focus of Infection
NCT02842437 ·Status: UNKNOWN ·Phase: NA
-
Effect of Renin-Angiotensin System on Platelet in Patient With Sepsis
NCT03952390 ·Status: COMPLETED
-
Study of Multiple-dose Kukoamine B Mesilate in Sepsis Patients
NCT03237728 ·Status: COMPLETED ·Phase: PHASE1
-
Reconstruction of Monocytic Immunocompetence by Granulocyte-macrophage-colony Stimulating Factor (GM-CSF) in Patients With Severe Sepsis and Septic Shock
NCT00252915 ·Status: COMPLETED ·Phase: PHASE2
-
Identification and Clinical Efficacy Analysis of Biomarkers in Sepsis Patients
NCT05911711 ·Status: UNKNOWN
-
Shenfu Injection Improves Arterial Vascular Reactivity
NCT03749525 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3